《JAMA,4月29日,Internet Searches for Unproven COVID-19 Therapies in the United States》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-05-02
  • Internet Searches for Unproven COVID-19 Therapies in the United States

    Michael Liu, AB1; Theodore L. Caputi, MPH2; Mark Dredze, PhD3; et alAaron S. Kesselheim, MD, JD, MPH4; John W. Ayers, PhD, MA5

    Author Affiliations Article Information

    JAMA Intern Med. Published online April 29, 2020. doi:10.1001/jamainternmed.2020.1764

    There are no highly effective prescription drug therapies supported by any reliable evidence for the ongoing coronavirus disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2. However, fears among the public can lead to searches for unproven therapies. Therefore, when several high-profile figures, including entrepreneur Elon Musk and President Donald Trump, endorsed the use of chloroquine, a malarial prophylaxis drug, and hydroxychloroquine (with the antibiotic azithromycin), a lupus and rheumatoid arthritis treatment, to treat COVID-19, it drew massive public attention that could shape individual decision-making.

  • 原文来源:https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2765361
相关报告
  • 《JAMA,5月28日,Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-05-29
    • Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States Muthiah Vaduganathan, MD, MPH1; Jeroen van Meijgaard, PhD2; Mandeep R. Mehra, MD, MSc1; et alJacob Joseph, MD3; Christopher J. O’Donnell, MD, MPH3; Haider J. Warraich, MD3 Author Affiliations Article Information JAMA. Published online May 28, 2020. doi:10.1001/jama.2020.9184 Conflicting information regarding the benefits of hydroxychloroquine/chloroquine and azithromycin in coronavirus disease 2019 (COVID-19) treatment and hypothetical concerns for drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), have challenged care during the pandemic.1 However, limited data are available about how prescription of these therapies has changed. The objective of this exploratory analysis was to evaluate prescription patterns of these therapies, along with other commonly used drugs for reference, in the United States during the COVID-19 pandemic. We hypothesized that the prescription of hydroxychloroquine/chloroquine and azithromycin would exceed historical estimates while ACE inhibitor/ARB use would be reduced.
  • 《4月29日_牛津大学等通过互联网搜索在美国未经证实的COVID-19治疗方法》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-01
    • 1.时间:2020年4月29日 2.机构或团队:牛津大学、加州大学圣地亚哥分校、约翰·霍普金斯大学,哈佛医学院 3.事件概要: 4月29日,JAMA inter med来自牛津大学,加州大学圣地亚哥分校,约翰•霍普金斯大学,哈佛医学院研究团队的题为“Internet Searches for Unproven COVID-19 Therapies in the United States”的文章。 该研究通过对互联网信息的分析评判美国民众对氯喹的关注和购买行为。结果显示,2月1日,3月16日,3月22日和3月29日购买氯喹的每1000万个Google搜索的查询分数(QF)分别为4.78(约为542次搜索),26.90(约为3052次搜索),66.16(约为7506次搜索)和19.19(约为2177次搜索)。2月1日,3月16日,3月22日和3月29日购买羟氯喹的QF分别为4.35(约为494次搜索),79.37(约为9006次搜索)和31.95(约为3625次搜索)。在备受瞩目的声称这些药物是有效的COVID-19疗法后,购买氯喹的查询增加了442%(95%CI,215%-1220%)。同样,购买羟氯喹的搜索量也增加了1389%(95%CI,779%-2021%)。搜索的第一个高峰和最大高峰分别与马斯克的推文和特朗普的第一则电视转播背书直接对应,后者于3月19日发生(氯喹QF 249.58 [估计的搜索28,319];羟氯喹QF 179.00 [20 311估计的搜索] )。这些变化分别比对氯喹和羟基氯喹的预期分别多出约93000和96000,在短短14天内,这两种药物的总搜索量为21.6万。 该文章报道称,在首次致命中毒的新闻报道之后,购买氯喹或羟氯喹的搜索量仍大大高于预期水平,分别高出212%(95%CI,66%-1098%)和1167%(95%CI,628%-1741%)。 该研究指出,备受瞩目的数据得到认可后,民众对氯喹和羟基氯喹的需求大幅度增加,即使据报道由于含氯喹的产品导致死亡之后,对氯喹和羟基氯喹的需求仍然很高。在公共卫生危机时期,不应由公众人士吹捧没有足够证据支持的疗法。产品背书可能导致对产品的无监督使用,对服用产品的人造成危险后果,而哄抢这些药物可能会导致出于健康原因而需要这些产品的短缺。在这种情况下,这些不利后果会更加严重,因为含氯喹的产品可通过亚马逊等网站向公众出售。 该文章指出,在推广这些药物时,有关氯喹和羟氯喹临床疗效的发现尚无定论。在发现这些或其他药物对COVID-19治疗有效之前,监管机构和面向公众的公司应积极减轻这种错误信息的负面影响。除非另有规定,否则美国食品药品监督管理局应警告公众不要购买未经批准的疗法。Google对COVID-19的响应是,将一个教育网站整合到与暴发相关的搜索结果中,并且可以扩展到包括未经批准的COVID-19疗法的搜索。同样,零售商必须建立警告或扣留可能与COVID-19处理有关的产品,例如eBay从其网站上取消氯喹的销售就是例证。 该研究指出,在这样的特殊时期,民众的担忧会使其寻求未经证实的COVID-19药物的需求激增,公共卫生领导者、监管机构、媒体和零售商必须传播准确的信息。 4.附件: 原文链接https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2765361